Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 9/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.39 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.39 |
| ▸ | FEN1 | P39748 | 3/20 | 0.39 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18005299 | 0.88 | TGFBR1 (0.52) | TGFBR1TGFBR2ALOX5APFEN1DGAT1 | |
| SCHEMBL18005344 | 0.84 | TGFBR1 (0.52) | TGFBR1ALOX5APFEN1 | |
| SCHEMBL18005280 | 0.81 | DGAT1 (0.36) | NR3C1ALOX5APFEN1PGRDGAT1 | |
| SCHEMBL5518025 | 0.75 | TRPA1 (0.60) | NR3C1ALOX5APFEN1PGRDGAT1 | |
| SCHEMBL759979 | 0.74 | CYP11B2 (0.43) | PGRDGAT1 | |
| SCHEMBL31378467 | 0.74 | PTPN11 (0.40) | ALOX5AP | |
| SCHEMBL3514238 | 0.72 | KDM4E (0.40) | ALOX5APFEN1DGAT1 | |
| SCHEMBL30112293 | 0.70 | GRIN1 (0.37) | NR3C1DGAT1HTR2AHTR2C | |
| SCHEMBL3514316 | 0.69 | CHEK1 (0.43) | ALOX5APFEN1DGAT1HTR2AHTR2C | |
| SCHEMBL31038849 | 0.69 | DGAT1 (0.35) | DGAT1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981944-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981944-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981944-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3259264-A1 | GDF-8 INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-12-27 | — | — | EP | disclosed |
| US-20160264553-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-15 | — | — | US | disclosed |
| US-20160264553-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-15 | — | — | US | disclosed |
| US-20160264553-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-15 | — | — | US | disclosed |
| WO-2016133838-A1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016133838-A1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264553-A1 | GDF-8 Inhibitors | CXCL8, MSTN, LGALS8 | TGFBR1 249/4885NR3C1 756/4885TGFBR2 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.